Finally, we showed that the KRAS blocker deltarasin acts to downregulate IL1R1 (interleukin-1 receptor 1) expression in KRAS-mutant tumor cells and that the proposed KRAS/CCL2/IL1B signature is enriched in human cancers with high KRAS mutation frequencies, in which it portends a dismal prognosis. This evidence concerns the gene CCL2 and neoplasm.